US real estate theme ETF: SPDR S&P Homebuilders ETF (XHB)

The U.S. real estate-themed ETF SPDR S&P Homebuilders ETF (ARCA: XHB) tracks the performance of the S&P Homebuilders Select Industry Index. The fund uses a sampling strategy. (At least 80%) invest in the securities that make up the index. This index represents the homebuilder category of the S&P Total Market Index (S&P TMI). The fund is non-diversified.

The Standard & Poor’s Home Builders Select Industry Index represents the home builder category of the Standard & Poor’s Total Market Index (S&P TMI). Standard & Poor’s TMI aims to track the entire US stock market. Standard & Poor’s TMI’s house builders segment includes the house construction sub-industry. The index was modified to equal weight.

SPDR S&P Homebuilders ETF:

  • The investment results that SPDR® S&P® Homebuilders ETF seeks to provide, before fees and expenses are deducted, usually correspond to the total return performance of the S&P® Homebuilders Select IndustryTM Index.
  • S&P TMI’s housing builder market segment includes the following sub-sectors: construction products, home decoration, home decoration retail, home retail and household appliances.
  • Seek to track the revised weighted average index, which provides unconcentrated industry exposure for large, medium and small-cap stocks.
  • Compared with traditional industry-based investments, investors are allowed to take strategic or tactical positions at a more targeted level.

US stock real estate ETFs also include:

  • U.S. Real Estate ETF-Vanguard Real Estate Index Fund ETF Shares (ARCA:VNQ)
  • US Real Estate ETF-iShares US Real Estate ETF (ARCA: IYR)
  • Residential Real Estate Trust ETF-iShares Residential and Multisector Real Estate ETF (ARCA: REZ)
  • International Real Estate ETF-SPDR Dow Jones International Real Estate ETF (ARCA:RWX)
  • International Developed Real Estate ETF-iShares International Developed Real Estate ETF (NASDAQ:IFGL)


Notify of
Inline Feedbacks
View all Intels

Clinical phase biopharmaceutical company: Onconova Therapeutics (ONTX)

Clinical stage biotechnology company: Shattuck Labs, Inc. (STTK) (2016)